Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder
- 30 September 2006
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 102 (3), 542-545
- https://doi.org/10.1016/j.ygyno.2006.01.029
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosisProceedings of the National Academy of Sciences of the United States of America, 2003
- Chemokines in cancerCytokine & Growth Factor Reviews, 2002
- The role of cytokines in the epithelial cancer microenvironmentSeminars in Cancer Biology, 2002
- Multiple Pathways for the Initiation of T Helper 2 (Th2) ResponsesThe Journal of Experimental Medicine, 1997
- RANTES Secretion by Gene-Modified Tumor Cells Results in Loss of TumorigenicityIn Vivo:Role of Immune Cell SubpopulationsHuman Gene Therapy, 1996
- A CYTOKINE PROFILE OF NORMAL AND MALIGNANT OVARYCytokine, 1996
- The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment.The Journal of Experimental Medicine, 1995
- The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.JCI Insight, 1995
- Medical Statistics: A Commonsense Approach.Biometrics, 1993
- Tribute to Patrick Steptoe: beginnings of laparoscopyHuman Reproduction, 1989